ArticleDiabetes research and clinical practice2026
Age at type 2 diabetes diagnosis, mortality, and health loss in South Asians.
Article in Diabetes research and clinical practice, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
objectiveWe examined associations between age at type 2 diabetes (T2D) diagnosis and long-term mortalityand lifetime health loss. RESEARCH DESIGN AND
methodsWe analyzed data from the population-based CARRS cohort. T2D was defined by self-report, glucose-lowering medication use, or glycemic thresholds and categorized by age at diagnosis (20-29, 30-39, 40-59, or ≥60 years). Hazard ratios (HRs) were estimated using time-dependent Cox models with participants without T2D as reference group. Model-based projections estimated years of life lost (YLL), years lived with disability (YLD), disability-adjusted life years (DALYs), and excess life-years lost (LYL).
resultsAmong 21,574 participants (mean age 43.3 years), 6,251 had diabetes. Over a median follow-up of 8.7 years, 2,163 deaths occurred. Younger age at T2D diagnosis was associated with higher risks of mortality and cardiovascular events. Adjusted HRs for all-cause mortality were 2.98 (95% CI 1.60-5.54) for T2D diagnosis at 20-29 years, 2.28 (1.74-2.98) at 30-39 years, 1.73 (1.47-2.04) at 40-59 years, and 1.61 (1.30-1.99) at ≥60 years. Projected lifetime DALYs were greatest with younger diagnosis, ranging from 24.5 years for diagnosis at 20-29 years to 5.5 years at > 60 years, with similar gradients for excess LYL.This pattern was also observed for CVD eventsacross age groups.
conclusionsT2D diagnosed at a younger age was associated with higher mortalityand greater LYL in South Asians.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.